Global Soft Tissue Sarcoma Market Research Report Information By Diagnosis (Biopsy, Ultrasound Scan, Magnetic Resonance Imaging, and others), By Treatment By End Use, And By Region Industry Forecast Till 2032

Description

List of Tables

Global Soft Tissue Sarcoma Market Research Report Information By Diagnosis (Biopsy, Ultrasound Scan, Magnetic Resonance Imaging (MRI), and others), By Treatment (Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drugs, Radiation Therapy, and Surgery) By End Use (Hospitals and Clinics, Cancer Research Centers, and Others), And By Region (North America, Europe, Asia-Pacific, And Rest of the World) Industry Forecast Till 2032

Overview of the Market

The market size for soft tissue sarcoma was estimated at USD 3,248.52 million in 2023 and is expected to reach USD 6,204.02 million by 2032, with a compound yearly growth rate (CAGR) of 7.67% from 2024 to 2032. The main market drivers boosting market growth include things like the introduction of new products, a rise in the usage of more recent treatments, and a wider target demographic.

The launch of new goods, the broad use of cutting-edge medications, and the broadening of the target market are important factors propelling market progress. The development of new treatments is one of the main factors driving the soft tissue sarcoma market. Innovative medications and treatments for soft tissue sarcoma have become incredibly available in the last ten years. The increased treatment options and improved efficacy made possible by these innovative medications are advantageous to both patients and physicians.

Perspectives on Market Segments

The global soft tissue sarcoma market has been divided into four segments based on type: angiosarcoma, gut stromal tumor (GIST), epithelioid sarcoma, and others. The Gastrointestinal Stromal Tumor (GIST) segment is the one with the quickest rate of growth during the projection period, while the Angiosarcoma segment had the largest market in 2023.

The global soft tissue sarcoma market has been divided into two segments based on diagnosis and treatment. In 2023, the Diagnostic segment dominated the market, and throughout the forecast period, the Treatment sector is expanding at the quickest rate. The diagnosis is further divided into magnetic resonance imaging (MRI), ultrasound scanning, biopsy, and additional procedures like X-rays and PET scans. Treatment was further divided into surgery, radiation therapy, chemotherapy, anti-angiogenic medications, and targeted therapy.

The global soft tissue sarcoma market has been divided into many segments, including cancer research centers and hospitals and clinics, based on the end user. During the projected period, the Hospitals and Clinics category is expected to grow at the quickest rate and hold the largest market in 2023.

Regional Perspectives

North America, Europe, Asia-Pacific, and the Rest of the World are the regions for which the study offers market information. In 2022, the soft tissue sarcoma market was dominated by North America, Europe, and Asia-Pacific. The high incidence of soft tissue sarcoma in North America and Europe, together with the existence of contemporary medical facilities and research and development activities in these areas, are the causes of this.

The second-largest shareholder in the global market for soft tissue sarcoma is the European market. In December 2021, Tazverik (tazemetostat) received conditional marketing authorization from the European Medicines Agency (EMA) to treat adult epithelioid sarcoma.

Additionally, throughout the course of the forecast period, the Asia Pacific Soft Tissue Sarcoma market is anticipated to expand at the quickest compound annual growth rate (CAGR). In September 2021, Ayvakit (avapritinib) was authorized by the China National Medical Products Administration (NMPA) to treat gastrointestinal stromal tumors (GIST), a type of soft tissue sarcoma, that are incurable or metastatic.

Key Players

Major players in the soft tissue sarcoma market are Johnson & Johnson Services Inc. (U.S.), Bristol-Myers Squibb (U.S.), F. Hoffmann-La Roche AG (Genentech) (Switzerland), Eli Lilly and Company (U.S.), Pfizer Inc. (U.S.), and GlaxoSmithKline plc (U.K.).

Product Code: MRFR/Pharma/3862-HCR

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

3.1 OVERVIEW
3.2 DATA FLOW
- 3.2.1 DATA MINING PROCESS
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
- 3.4.1 SECONDARY RESEARCH DATA FLOW:
3.5 PRIMARY RESEARCH:
- 3.5.1 PRIMARY RESEARCH DATA FLOW:
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
- 3.6.1 REVENUE ANALYSIS APPROACH
3.7 DATA FORECASTING
- 3.7.1 DATA FORECASTING TYPE
3.8 DATA MODELING
- 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
- 3.8.2 DATA MODELING:
3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

4.1 INTRODUCTION
4.2 DRIVERS
- 4.2.1 INCREASING INCIDENCE OF SOFT TISSUE SARCOMAS
- 4.2.2 RISING AWARENESS ASSOCIATED WITH SOFT TISSUE SARCOMA
- 4.2.3 GROWING APPROVAL OF INNOVATIVE TREATMENT FOR SOFT TISSUE SARCOMA
4.3 RESTRAINTS
- 4.3.1 SIDE-EFFECTS OF SOFT TISSUE SARCOMA DRUGS
- 4.3.2 VOLUNTARY PRODUCT RECALLS BY MARKET PLAYERS
4.4 OPPORTUNITY
- 4.4.1 GROWING GERIATRIC POPULATION
- 4.4.2 INVESTMENTS IN RESEARCH AND DEVELOPMENT
- 4.4.3 ONGOING CLINICAL TRIALS FOR SOFT TISSUE SARCOMA

5 MARKET FACTOR ANALYSIS

5.1 PORTER'S FIVE FORCES MODEL
- 5.1.1 THREAT OF NEW ENTRANTS
- 5.1.2 BARGAINING POWER OF SUPPLIERS
- 5.1.3 THREAT OF SUBSTITUTES
- 5.1.4 BARGAINING POWER OF BUYERS
- 5.1.5 INTENSITY OF RIVALRY
5.2 IMPACT OF COVID-19 ON GLOBAL SOFT TISSUE SARCOMA MARKET
5.3 KEY MARKET TRENDS IN THE CHINA SOFT TISSUE SARCOMA MARKET
5.4 TECHNOLOGICAL ADVANCEMENTS IN CHINA
5.5 REGULATORY FRAMEWORK IN CHINA
5.6 PIPELINE ANALYSIS IN CHINA
5.7 AVERAGE PRICING OF PRODUCTS IN CHINA, 2023

6 GLOBAL SOFT TISSUE SARCOMA MARKET, BY TYPE

6.1 OVERVIEW
6.2 ANGIOSARCOMA
6.3 EPITHELIOID SARCOMA
6.4 GASTROINTESTINAL STROMAL TUMOR (GIST)
6.5 OTHERS

7 GLOBAL SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS AND TREATMENT

7.1 OVERVIEW
7.2 DIAGNOSIS
- 7.2.1 BIOPSY
- 7.2.2 ULTRASOUND SCAN
- 7.2.3 MAGNETIC RESONANCE IMAGING (MRI)
- 7.2.4 OTHERS
7.3 TREATMENT
- 7.3.1 TARGETED THERAPY
- 7.3.2 CHEMOTHERAPY
- 7.3.3 ANTI-ANGIOGENESIS DRUGS
- 7.3.4 RADIATION THERAPY
- 7.3.5 SURGERY

8 GLOBAL SOFT TISSUE SARCOMA MARKET, BY END USER

8.1 OVERVIEW
8.2 HOSPITALS AND CLINICS
8.3 CANCER RESEARCH CENTERS
8.4 OTHERS

9 GLOBAL SOFT TISSUE SARCOMA MARKET, BY REGION

9.1 OVERVIEW
9.2 NORTH AMERICA
- 9.2.1 US
- 9.2.2 CANADA
9.3 EUROPE
- 9.3.1 GERMANY
- 9.3.2 FRANCE
- 9.3.3 UK
- 9.3.4 ITALY
- 9.3.5 SPAIN
- 9.3.6 RUSSIA
- 9.3.7 REST OF EUROPE
9.4 ASIA-PACIFIC
- 9.4.1 CHINA
- 9.4.2 INDIA
- 9.4.3 JAPAN
- 9.4.4 SOUTH KOREA
- 9.4.5 MALAYSIA
- 9.4.6 THAILAND
- 9.4.7 INDONESIA
- 9.4.8 REST OF ASIA-PACIFIC
9.5 SOUTH AMERICA
- 9.5.1 BRAZIL
- 9.5.2 MEXICO
- 9.5.3 ARGENTINA
- 9.5.4 REST OF SOUTH AMERICA
9.6 MIDDLE EAST AND AFRICA
- 9.6.1 GCC COUNTRIES
- 9.6.2 SOUTH AFRICA
- 9.6.3 REST OF MIDDLE EAST AND AFRICA

10 COMPETITIVE LANDSCAPE

10.1 INTRODUCTION
10.2 MARKET SHARE ANALYSIS, 2023
10.3 COMPETITOR DASHBOARD
10.4 PUBLIC PLAYERS STOCK SUMMARY
10.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 10.6.1 PRODUCT APPROVAL
- 10.6.2 COLLABORATION
- 10.6.3 PRODUCT LAUNCH

11 COMPANY PROFILES

11.1 GE HEALTHCARE
- 11.1.1 COMPANY OVERVIEW
- 11.1.2 FINANCIAL OVERVIEW
- 11.1.3 PRODUCTS/SERVICES OFFERED
- 11.1.4 KEY DEVELOPMENTS
- 11.1.5 SWOT ANALYSIS
- 11.1.6 KEY STRATEGIES
11.2 CANON MEDICAL SYSTEMS CORPORATION
- 11.2.1 COMPANY OVERVIEW
- 11.2.2 FINANCIAL OVERVIEW
- 11.2.3 PRODUCT OFFERED
- 11.2.4 KEY DEVELOPMENTS
- 11.2.5 KEY STRATEGIES
11.3 NOVARTIS AG
- 11.3.1 COMPANY OVERVIEW
- 11.3.2 FINANCIAL OVERVIEW
- 11.3.3 PRODUCTS OFFERED
- 11.3.4 KEY DEVELOPMENTS
- 11.3.5 SWOT ANALYSIS
- 11.3.6 KEY STRATEGIES
11.4 F. HOFFMANN-LA ROCHE LTD.
- 11.4.1 COMPANY OVERVIEW
- 11.4.2 FINANCIAL OVERVIEW
- 11.4.3 PRODUCTS OFFERED
- 11.4.4 KEY DEVELOPMENTS
- 11.4.5 SWOT ANALYSIS
- 11.4.6 KEY STRATEGIES
11.5 BLUEPRINT MEDICINES CORPORATION
- 11.5.1 COMPANY OVERVIEW
- 11.5.2 FINANCIAL OVERVIEW
- 11.5.3 PRODUCTS OFFERED
- 11.5.4 KEY DEVELOPMENTS
- 11.5.5 KEY STRATEGIES
11.6 JOHNSON & JOHNSON INC.
- 11.6.1 COMPANY OVERVIEW
- 11.6.2 FINANCIAL OVERVIEW
- 11.6.3 PRODUCTS OFFERED
- 11.6.4 KEY DEVELOPMENTS
- 11.6.5 SWOT ANALYSIS
- 11.6.6 KEY STRATEGIES
11.7 BRISTOL-MYERS SQUIBB COMPANY
- 11.7.1 COMPANY OVERVIEW
- 11.7.2 FINANCIAL OVERVIEW
- 11.7.3 PRODUCTS OFFERED
- 11.7.4 KEY DEVELOPMENTS
- 11.7.5 KEY STRATEGIES
11.8 EISAI CO., LTD
- 11.8.1 COMPANY OVERVIEW
- 11.8.2 FINANCIAL OVERVIEW
- 11.8.3 PRODUCTS OFFERED
- 11.8.4 KEY DEVELOPMENTS
- 11.8.5 SWOT ANALYSIS
- 11.8.6 KEY STRATEGIES
11.9 SIEMENS HEALTHINEERS
- 11.9.1 COMPANY OVERVIEW
- 11.9.2 FINANCIAL OVERVIEW
- 11.9.3 PRODUCTS OFFERED
- 11.9.4 KEY DEVELOPMENTS
- 11.9.5 SWOT ANALYSIS
- 11.9.6 KEY STRATEGIES
11.10 ELI LILLY AND COMPANY
- 11.10.1 COMPANY OVERVIEW
- 11.10.2 FINANCIAL OVERVIEW
- 11.10.3 PRODUCTS OFFERED
- 11.10.4 KEY DEVELOPMENTS
- 11.10.5 KEY STRATEGIES

12 DATA CITATIONS